Macugen Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The macugen market research report is one of a series of new reports that provides macugen market statistics, including the macugen industry global market size, regional shares, competitors with the macugen market share, detailed macugen market segments, market trends, and opportunities, and any further data you may need to thrive in the macugen industry. This macugen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increased diagnosis and treatment rates, increasing prevalence of wet AMD, rising prevalence of AMD, increasing investment for healthcare infrastructure, and rising awareness of diabetic eye complications. Major trends in the forecast period include a shift toward combination therapies, advancements in drug delivery systems, technological innovations in ophthalmology, technological advancement in diagnostic methods, and developing advanced treatments for AMD.

The increasing prevalence of age-related macular degeneration (AMD) is expected to drive significant growth in the macugen market in the coming years. AMD is a progressive eye disease that affects the macula, the part of the retina responsible for clear and sharp vision. This rise in AMD cases can be attributed to factors such as an aging global population, longer life expectancies, and lifestyle choices such as smoking, poor diet, and prolonged exposure to UV light. Macugen is beneficial for treating AMD as it works by inhibiting vascular endothelial growth factor (VEGF), which helps reduce the growth and leakage of abnormal blood vessels in the retina. This treatment can slow the progression of the disease and preserve vision. According to the National Center for Biotechnology Information, by 2040, around 288 million people are projected to be affected by AMD. As a result, the increasing prevalence of the condition is contributing to the growth of the macugen market.

The growing emphasis on eye care is also expected to boost the growth of the macugen market. Eye care involves practices and treatments aimed at maintaining or improving vision and overall eye health. This increased focus is largely due to the rising prevalence of eye conditions, an aging population, and greater awareness about the importance of eye health. Macugen plays a key role in eye care by helping treat AMD, preventing abnormal blood vessel growth in the retina, and thereby preventing vision loss and improving visual clarity. In November 2023, the International Agency for the Prevention of Blindness (IAPB) coordinated the Love Your Eyes campaign, which generated significant engagement, including 20 parliamentary screenings, more than 6.5 million consumer pledges, and over 542 million media impressions, highlighting the growing awareness and focus on eye health. As a result, this increasing attention to eye care is fueling growth in the macugen market.

A significant trend in the macugen market is the emergence of gene therapy as a treatment option for AMD. Gene therapy involves the introduction of genetic material into a patient's cells to treat or prevent diseases by targeting the underlying causes. In 2023, Regenxbio, a U.S.-based biotechnology company, launched RGX-314, a gene therapy product designed to deliver a gene encoding an anti-VEGF protein directly into the eye. This innovative therapy aims to offer long-lasting results by reducing the need for frequent injections. RGX-314 stands out due to its potential for a single administration, which could significantly improve patient compliance, and its ability to address the root causes of AMD rather than merely managing the symptoms. These developments position companies such as Regenxbio as key players in the evolving field of ocular therapies, further contributing to the growth of the macugen market.

The key company operating in the macugen market is Bausch + Lomb Inc.

North America was the largest region in the macugen market in 2024. The regions covered in macugen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the macugen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Macugen (pegaptanib sodium) is an anti-vascular endothelial growth factor (VEGF) medication designed to treat retinal conditions by inhibiting the formation of abnormal blood vessels in the eye. Its primary purpose is to reduce vision loss and prevent further damage caused by these irregular blood vessels. The recommended dose of Macugen is 0.3 mg, administered once every six weeks by an ophthalmologist under sterile conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Macugen is primarily indicated for treating wet age-related macular degeneration (AMD) and diabetic macular edema. Wet AMD is a progressive eye disease characterized by the growth of abnormal blood vessels beneath the retina, which can lead to central vision loss. The medication is available in various formulations, including intravitreal injections and extended-release forms. It is distributed through hospitals, clinics, and both retail and specialty pharmacies. Macugen is prescribed to adult and geriatric patients, among other groups.

The macugen market consists of sales of pegaptanib sodium injections and pre-filled syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.